One effective CRS treatment, anakinra, is a recombinant human IL-1 receptor antagonist that has been shown in previous studies to be safe and effective for alleviating CRS, thus confirming that IL-1 is a central player in severe sepsis-associated cytokine storms and a potential therapeutic target [90,91]. Here, IL1A is linked to congenital rubella syndrome.